{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:40:56Z","timestamp":1791945656960,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.pbb.2019.172839","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T12:29:46Z","timestamp":1576758586000},"page":"172839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling"],"prefix":"10.1016","volume":"188","author":[{"given":"Yunfei","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youge","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyu","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2019.172839_bb0005","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI43992","article-title":"Identification of a low\u2013molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice","volume":"121","author":"Cazorla","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pbb.2019.172839_bb0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/1570159X15666170221101054","article-title":"Beyond ketamine: new approaches to the development of safer antidepressants","volume":"15","author":"Chaki","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2019.172839_bb0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.172839_bb0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-319-57193-5_9","article-title":"Schizophrenia: basic and clinical","volume":"15","author":"Coyle","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.pbb.2019.172839_bb0025","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pbb.2019.172839_bb0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/schbul\/sbs011","article-title":"Phencyclidine\/schizophrenia: one view toward the past, the other to the future","volume":"38","author":"Domino","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pbb.2019.172839_bb0035","series-title":"Ketamine and Rapid-acting Antidepressants: A New Era in the Battle Against Depression and Suicide. F1000Res. 7, Rev-659","author":"Duman","year":"2018"},{"key":"10.1016\/j.pbb.2019.172839_bb0040","article-title":"MPTP-induced dopaminergic neurotoxicity in mouse striatum is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling","author":"Fujita","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172839_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"361","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2019.172839_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pbb.2010.11.009","article-title":"The treatment of cognitive impairment in schizophrenia","volume":"99","author":"Goff","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.172839_bb0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0060","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14728222.2014.934225","article-title":"Targeting of NMDA receptors in new treatments for schizophrenia","volume":"18","author":"Hashimoto","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.pbb.2019.172839_bb0065","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1017\/S0033291716000969","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity","volume":"46","author":"Hashimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pbb.2019.172839_bb0070","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/14728222.2016.1238899","article-title":"Ketamine\u2019s antidepressant action: beyond NMDA receptor inhibition","volume":"20","author":"Hashimoto","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.pbb.2019.172839_bb0075","first-page":"75","article-title":"Recent advances in the early intervention in schizophrenia: future direction from preclinical findings","volume":"21","author":"Hashimoto","year":"2019","journal-title":"Curr. Psychiatr. Rev."},{"key":"10.1016\/j.pbb.2019.172839_bb0080","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pbb.2019.172839_bb0085","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors","volume":"32","author":"Hashimoto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2019.172839_bb0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172839_bb0090","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective \u03b17 nicotinic receptor agonist SSR180711","volume":"63","author":"Hashimoto","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pbb.2019.172839_bb0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pbb.2019.172839_bb0110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/npp.2014.207","article-title":"Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D\u2083-5-HT\u2082A and D\u2081-NMDA receptors in the mPFC","volume":"40","author":"Hida","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2019.172839_bb0115","article-title":"Esketamine for treatment resistant depression","volume":"366","author":"Jauhar","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.pbb.2019.172839_bb0120","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0125","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/schbul\/sbs069","article-title":"Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia","volume":"38","author":"Javitt","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pbb.2019.172839_bb0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2019.172839_bb0135","article-title":"Esketamine: a glimmer of hope in treatment-resistant depression","author":"Kaur","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pbb.2019.172839_bb0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0145","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2019.172839_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pbb.2018.09.006","article-title":"The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia","volume":"175","author":"Li","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.172839_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fpsyt.2019.00093","article-title":"Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Psych."},{"key":"10.1016\/j.pbb.2019.172839_bb0160","article-title":"Novel treatment for the hardest-to-treat schizophrenia: dual action of NMDA receptor and antioxidant","author":"Lin","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.pbb.2019.172839_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2018.02.034","article-title":"Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia","volume":"263","author":"Man","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2019.172839_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22126","article-title":"(R)- and (S)-ketamine induce differential fMRI responses in conscious rats","volume":"73","author":"Masaki","year":"2019","journal-title":"Synapse"},{"key":"10.1016\/j.pbb.2019.172839_bb0175","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1176\/appi.ajp.2019.19060631","article-title":"Esketamine and the need for a new type of registry for drugs with abuse potential","volume":"176","author":"McShane","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.coph.2004.08.008","article-title":"PCP: from pharmacology to modelling schizophrenia","volume":"5","author":"Morris","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172839_bb0185","article-title":"The origin of NMDA receptor hypofunction in schizophrenia","author":"Nakazawa","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbb.2019.172839_bb0190","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1038\/tp.2015.157","article-title":"BDNF\u2013TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms","volume":"5","author":"Ren","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0195","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiat."},{"key":"10.1016\/j.pbb.2019.172839_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127244","article-title":"Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood","volume":"10","author":"Shirai","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2019.172839_bb0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2215-0366(17)30102-5","article-title":"Ketamine treatment for depression: opportunities for clinical innovation and ethica foresight","volume":"4","author":"Singh","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0210","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12031-010-9447-5","article-title":"Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain","volume":"43","author":"Snigdha","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.pbb.2019.172839_bb0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","article-title":"Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine","volume":"172","author":"Tian","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.172839_bb0220","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0230","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2019.172839_bb0235","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","article-title":"Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine","volume":"239","author":"Yang","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2019.172839_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0245","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.psychres.2019.01.051","article-title":"Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia","volume":"273","author":"Yang","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2019.172839_bb0250","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172839_bb0255","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pbb.2014.06.008","article-title":"Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors","volume":"124","author":"Yoshimi","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.172839_bb0260","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2019.172839_bb0265","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolites pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2019.172839_bb0270","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.pbb.2019.172839_bb0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00213-012-2643-y","article-title":"Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia","volume":"222","author":"Zhang","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172839_bb0280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.172839_bb0285","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1007\/s00213-015-4062-3","article-title":"Comparison of ketamine, 7, 8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression","volume":"232","author":"Zhang","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172839_bb0290","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-018-4835-6","article-title":"Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172839_bb0295","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12264-016-0081-2","article-title":"Risks associated with misuse of ketamine as a rapid-acting antidepressant","volume":"32","author":"Zhu","year":"2016","journal-title":"Neurosci. Bull."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130571930588X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130571930588X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:37:55Z","timestamp":1758775075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009130571930588X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":59,"alternative-id":["S009130571930588X"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172839","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172839"}}